Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center , University Medical Center, shared on X:
“Getting late to this review on resistance to ICIs in NSCLC by Cassio Murilo T. Hidalgo Filho and Biagio Ricciuti at Journal of Clinical Oncology.
Take: This is one of the biggest challenges in NSCLC. After resistance to ICIs, treatments become toxic and less effective. This is NOT one size fits all. We will require multiple solutions for complex mechanisms of resistance.
I see STK11/KEAP1 comutation subgroup as one of the biggest challenges and TGF B as a promising candidate.”
Title: Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
Authors: Cassio Murilo Hidalgo-Filho, Valentina Santo, Eleonora Gariazzo, Mihaela Aldea, Federica Pecci, François-Xavier Danlos, Gilberto de Castro Junior, Biagio Ricciuti
Read the full article.
Adjuvant Icotinib Linked to Better DFS in Resected Stage IA EGFR-Mutant Lung Adenocarcinoma
